Send to:

Choose Destination
See comment in PubMed Commons below
Artif Cells Nanomed Biotechnol. 2014 Jul 31:1-8. [Epub ahead of print]

Pre-exposure prophylaxis of HIV: A right way to go or a long way to go?

Author information

  • 1Shijiazhuang Center for Disease Control and Prevention , Shijia Zhuang , China.


Antiretroviral drugs are being tried as candidates for the pre-exposure prophylaxis (PrEP) against HIV for a considerable period, due to their potential for immediate inhibition of viral replication. Discrepancies in the findings called for a critical review of the relevant efforts and their outcomes. A systematic literature search identified 143 eligible articles of which only 5 reported complete findings while another 11 were still on-going. Observed moderate efficacy and good safety profile seemed to identify PrEP as a promising step for minimizing the spread of HIV to relatively unaffected population and controlling the epidemic among high risk population groups. But the duration of this efficacy was found to depend heavily on the availability, adherence and other related issues like cost, political commitment, ethical consideration etc. To prevent potential cultural and behavioral modifications, proper pre-administration counseling also seemed critical for the success of PrEP as a cost-effective intervention with adequate coverage.


HIV prevention; antiretroviral therapy; controlling the HIV epidemic; pre-exposure prophylaxis; prevention of HIV spread

[PubMed - as supplied by publisher]
[Available on 2016-01-31]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Write to the Help Desk